Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2012-03-13 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir offentliggör nya studier i fas III-programmet för TMC435
Regulatory Filings Classification · 95% confidence The document is a press release dated March 13, 2012, announcing that Medivir has initiated dosing/screening in two new Phase III clinical studies (HPC3001 and HPC3011) for its drug candidate TMC435 for Hepatitis C treatment. This is an announcement about ongoing clinical development and research activities, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It details scientific progress and study designs. Since it is a specific announcement regarding clinical trials and research updates, it does not fit neatly into the primary financial reporting categories. Given the options, it is best classified as a general announcement or regulatory filing that doesn't fit elsewhere, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but as a press release detailing R&D progress, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard corporate updates, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are clearly incorrect. Since it is a specific update on drug development, and not a standard financial report, RNS is the best fit among the provided codes for a general corporate announcement of this nature.
2012-03-13 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Medivir AB for the period 1 January – 31 December 2011. It contains comprehensive financial statements, including income statements, balance sheet summaries, and detailed management commentary on business performance, R&D, and future outlook. It is a full interim/quarterly report covering the fiscal year, not merely an announcement or a short summary. FY 2011
2012-02-23 Swedish
Earnings Release 2011
Earnings Release Classification · 99% confidence The document explicitly states it is publishing the "Financial Statement, 1 January – 31 December 2011" and provides a "Summary of the financial year (January – December)" along with detailed financial tables and a CEO's comment on the year's performance. The text also mentions the release of the "Interim Report for the period 1 January – 31 December 2011". Since the document covers a full fiscal year (January to December) and contains comprehensive financial details, it aligns best with the definition of an Annual Report (10-K). Although it uses the term 'Interim Report' in the context of the press release date (Feb 2012) for the full year 2011 results, the scope (full year) and depth of financial data strongly suggest it is the primary annual filing, which corresponds to the 10-K category in this classification scheme, rather than a quarterly 'Interim Report' (IR). The length (over 74k characters) also supports it being a full report, not just an announcement (RPA/RNS). FY 2011
2012-02-23 English
Valberedningens förslag till ny styrelse inför årsstämman 2012
Board/Management Information Classification · 99% confidence The document is a press release dated February 16, 2012, titled "Valberedningens förslag till ny styrelse inför årsstämman 2012" (The Nomination Committee's proposal for a new board ahead of the 2012 Annual General Meeting). This explicitly concerns the composition of the board proposed for the upcoming AGM. This falls under the scope of materials related to the Annual General Meeting (AGM) or governance/management proposals leading up to it. While it relates to the board (MANG) and governance (CGR), the context is specifically tied to the AGM proposals. The definition for AGM Information (AGM-R) covers "Presentations and materials shared during the Annual General Meeting (AGM)". Since this is a proposal *for* the AGM, it is closely related. However, the proposal for board members is a key component of the materials presented to shareholders for voting, which is often covered by proxy statements (PSI) or governance documents. Given the specific focus on the *Nomination Committee's proposal for the board* ahead of the AGM, and the fact that the final detailed proposal will be in the AGM notice, the most fitting category among the choices that deals with board composition proposals for the meeting is often related to the meeting itself or management changes. Since it is a proposal *for* the AGM, and not the final voting results (DVA) or the full proxy solicitation (PSI), and it details management/director changes (MANG), I must choose the best fit. The content is a direct announcement of proposed director changes, which strongly aligns with Board/Management Information (MANG). However, since the entire context is framed around the upcoming 'årsstämman' (AGM), AGM-R is also highly relevant. Given the specific nature of proposing directors, MANG is a strong candidate, but AGM-R covers materials *for* the AGM. Since the document explicitly states the proposal will be fully detailed in the 'kallelsen till årsstämman' (notice of the AGM), and this is a pre-notice announcement about the board composition, MANG (Board/Management Information) is the most precise classification for the content itself (director nominations). I will select MANG as it describes the core subject matter (board composition proposal).
2012-02-16 Swedish
Nomination Committee proposal for the Board for the 2012 Annual General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'Nomination Committee proposal for the Board for the 2012 Annual General Meeting' and details the proposed re-election and election of board members for the upcoming AGM. This content directly relates to the governance and composition of the board, which is a key component of Annual General Meeting materials. Since it is a proposal *for* the AGM, and not the final voting results (DVA) or a general governance report (CGR), the most fitting category is AGM Information (AGM-R). The document is short and announces proposals that will be detailed in the official AGM notice, but the core subject matter is the AGM agenda item regarding the board.
2012-02-16 English
Medivir’s partner GSK initiates OTC launch of Xerclear® in Europe under trade names Zoviduo and Zovirax Duo
Regulatory Filings Classification · 93% confidence The document is titled "Press Release February 8, 2012" and announces the OTC launch of a product (Xerclear®) by a partner (GSK) in Europe. It details commercial agreements, milestone payments, and product information. This format—a formal announcement of a business event, partnership update, or product launch, issued as a press release—does not fit the specific regulatory filings like 10-K, IR, or ER (which focuses on financial results). It is not a transcript (CT), a proxy statement (PSI), or a director's dealing report (DIRS). Since it is a general corporate announcement regarding commercial activity and partnership execution, and it is not a specific regulatory filing like a DEF 14A or a DVA, the most appropriate general category for a corporate announcement that doesn't fit the highly specific financial/regulatory types is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere. However, given the content is a commercial/business update, and not a mandatory regulatory filing like a 8-K or 6-K, RNS is the best fit among the provided options for a general press release.
2012-02-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.